Trial site
San Francisco
San Francisco, California 94115, United StatesNot linked to an institution yet
- 11running trials
- 6closed trials
The trials here
What the 17 trials at this site are about, from their registry records.
- Phase
- Phase 37 trials
- Phase 26 trials
- Phase 12 trials
- Phase 41 trial
- Status
- Active, not recruiting11 trials
- Completed5 trials
- Terminated1 trial
- Lead sponsor
- GlaxoSmithKline7 trials
- ViiV Healthcare6 trials
- Tesaro, Inc.4 trials
Running trials
Active, not recruiting
A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)
NCT06537414· Phase 2· GlaxoSmithKline· Source
Active, not recruiting
Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)
NCT06497504· Phase 2· GlaxoSmithKline· Source
Active, not recruiting
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
NCT05996471· Phase 2· ViiV Healthcare· Source
Active, not recruiting
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
NCT05277051· Phase 1· GlaxoSmithKline· Source
Active, not recruiting
Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease
NCT04915755· Phase 3· GlaxoSmithKline· Source
Active, not recruiting
Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults
NCT03299049· Phase 3· ViiV Healthcare· Source
Active, not recruiting
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
NCT02951052· Phase 3· ViiV Healthcare· Source
Active, not recruiting
Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants
NCT02938520· Phase 3· ViiV Healthcare· Source
Active, not recruiting
A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
NCT02655016· Phase 3· Tesaro, Inc.· Source
Active, not recruiting
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
NCT02715284· Phase 1· Tesaro, Inc.· Source
Active, not recruiting
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
NCT02362503· Phase 3· ViiV Healthcare· Source
Report an error